93 results about "Complement system" patented technology

The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.

The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.

Administering water-soluble or dispersible synthetic analogs or derivatives of astaxanthin, lutein, zeaxanthin, or lycophyll and/or other carotenoids to a subject may reduce some of the adverse effects of inflammation in a body organ or tissue. The analogs or derivatives may be incorporated into pharmaceutical, over-the-counter, or nutraceutical preparations. Administration of the analogs or derivatives described herein may reduce deposition of inflammatory mediators such as C-reactive protein, complement system proteins or the membrane attack complex (MAC) in tissues. Reduced deposition of these molecules in tissues may reduce cell damage and/or lysis in the tissues.

The present invention features the use of selected complement activation inhibitor(s) for treating an individual who has suffered a severe injury. The complement activation inhibitor acts at or above the level of C3 activation and does not significantly deplete or irreversibly inhibit complement activation. Also provided are compositions and methods for repleting and/or enhancing complement activation capacity in a subject who has suffered a traumatic injury.

Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method.

Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders.

Methods and compositions for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in ovarian cancer. In preferred embodiments, the body sample is a serum sample. The biomarkers of the invention include any genes or proteins that are selectively overexpressed in ovarian cancer, including, for example, acute phase reactants, lipoproteins, proteins involved in the regulation of the complement system, regulators of apoptosis, proteins that bind hemoglobin, heme, or iron, cytostructural proteins, enzymes that detoxify metabolic byproducts, growth factors, and hormone transporters. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.

The invention discloses a water complementing system for a fish-way entrance, which has good fish attracting effects. The water complementing system comprises a water complementing pool, wherein a water completing header tube is connected on the water complementing pool; at least one water complementing sub tube is connected on the water complementing header tube; a plurality of water complementing branch tubes are connected on the water complementing sub tube. The water complementing system adopts a sectional water complementing manner to simultaneously complement water for a plurality of positions of the fish-way entrance, so that water flow speed of the whole fish-way entrance is simultaneously changed without destroying the flow regime at the fish-way entrance, the flow regime at the fish-way entrance is kept to be stable to effectively attract fishes to enter the fish-way, thereby achieving good fish attracting effects; moreover, a plurality of water complementing branch tubes are adopted to complement water, and flow speed at the exit of each water complementing branch tube is not too large, so that large interferences cannot be caused to the flow speed of the fish-way, the tracing of fishes is not affected and is not blocked. The water complementing system is suitable for popularization and application in the fish-way field.

The present invention relates to a fusion protein capable of activating the complement system, the fusion protein comprising a first polypeptide sequence derived from a lectin-complement pathway activating protein or a functional homologue thereof; and a second polypeptide sequence derived from a collectin or a functional homologue thereof; wherein said complement activating protein is not a collectin. A preferred fusion protein comprises amino acids of the L-ficolin sequence of FIG. 1 and amino acids of the MBL sequence shown in FIG. 2. The fusion protein is suitable for use in treatment consisting of creation, reconstitution, enhancing and/or stimulating the opsonic and/or bactericidal activity of the complement system, i.e. enhancing the ability of the immune defence to recognise and kill microbial pathogens, and accordingly, the invention relates to a medicament comprising the fusion protein, methods for producing said fusion protein and methods for treating diseases, in particular infections.

Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3′ conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3′ A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3′-conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3-conjugate. For example, if the protein in the DNA-protein conjugate is the first component of the complement cascade (Clq or Clqrs) and the DNA aptamer has been developed against surface components of a target cell, it can be used to treat bacterial or parasitic infections and cancers. If the protein is serum albumin or another common (nonimmunogenic) blood protein and the aptamer is directed against a toxin or venom, the aptamer-protein conjugate can be used as an antidote that binds and neutralizes the toxin or venom. Similar DNA (aptamer)-nanotube, -enzyme, and -toxin conjugates could also be used to target and selectively kill bacteria, parasites, and cancer cells in vivo. If the protein is an Fc antibody fragment or C3b protein from the complement system and the aptamer is developed against a bacterial cell capsular material, other cell surface component or viral cell surface component, then the aptamer-3′-protein conjugate can aid in opsonization of the target cells or viruses by phagocytic leukocytes.

The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.

The invention relates to methods for treating tissue injury and/or afflictions, by administering a prophylactically or therapeutically effective amount of particulate, bioavailable β(1-3;1-6) glucan. The invention also relates to methods in which β(1-3;1-6) glucan is provided in the form of whole glucan particles, microparticulate β-glucan particles or a combination thereof. The invention also relates to method of enhancing glucan-mediated committed stem cell proliferation and expansion after injury via the complement system.

This disclosure describes a composition and method of magenitic nanoparticles (MNP) that are bound to a baculovirus (BV). The MNP-BV can be systemically administered to a patient, and a strong magnetic field applied to the target btissue, thus allowing uptake and expression only in the target tissue. Off-target effects are not seen because the MNP-BC is inactivated by the complement system outside of the magnetic field.

The invention relates to a heat supply network balance control system. The technical problems that hydraulic imbalance is not completely solved and interfere of outdoor temperature changes exists aresolved. The heat supply network balance control system comprises a site device, a first upper computer and a whole network balance module connected with the site device and the first upper computer sequentially through a communication network and a data bus, and the whole network balance module is arranged in a server located in a second upper computer. The site device comprises a first sensor, anelectric valve, a distributed variable frequency pump, a second sensor, a circulating water pump, a water complementing system and a field controller, wherein the first sensor, the electric valve andthe distributed variable frequency pump are arranged on a primary network; the second sensor, the circulating water pump and the water complementing system are disposed on a secondary network; and the field controller is used for controlling the electric valve, the distributed variable frequency pump and the water complementing system. The first sensor and the second sensor each include an outdoor temperature sensor. Through the technical scheme, the problem is solved well, and the heat supply network balance control system can be used for heat supply network balance control of centralized heating.

This invention provides methods of inducing the production of pro-inflammatory cytokines by activating Toll like Receptor (TLR) and the complement system. This invention further provides vaccines that contain compounds that activate a Toll like Receptor (TLR) and the complement system.

The invention belongs to the field of Chinese pharmaceutical technology, and relates to application of flavonoids compounds(formula I) in the preparation of anticomplement medicaments. The flavonoids compounds are extracted from ethyl acetate of Sophora flavescens, and in vitro anticomplementary activity screening tests of the flavonoids compounds prove that the flavonoids compounds have quite good effect of inhibiting the classical pathway and the alternative pathway of a complement system. The CH50 of the effect of the flavonoids compounds in inhibiting the classical pathway is 0.12+/-0.02mg/mL to 0.35+/-0.03mg/mL, and the AP50 of the effect of the flavonoids compounds in inhibiting the alternative pathway is 0.45+/-0.05mg/mL. The flavonoids compounds can be furthered used for preparing the anticomplement medicaments.

The invention relates to a phenolic acid compound and use thereof in the preparation of anticomplementary medicaments. The phenolic acid compound has a chemical structure formula shown in the specification; when R1 is COOH, and R2 is OCH3, the compound is vanillic acid; and when R1 is-CH=CH-COOH, and R2 is H, the compound is para-hydroxycinnamic acid. The invention has the advantages that the phenolic acid compound is directly extracted from natural product, and the compounds of vanillic acid and para-hydroxycinnamic acid have better inhibition function to the classical pathway of a complement system.

The invention belongs to the field of Chinese pharmaceutical manufacturing and relates to macrocyclic germacrane sesquiterpenoids as shown in the formula I and their novel uses in the preparation of anticomplementary drugs. Three macrocyclic germacrane sesquiterpenoids are separated from a petroleum ether extraction fraction of dried all-grass ethanol extract of Viola yedoensis Makino and are proved to have inhibitory effects of different degrees upon classical and alternative pathways of a complement system. The sesquiterpenoids can be prepared into anticomplementary drugs and further be prepared into drugs for treating complement-related diseases.

Compounds comprising peptides and peptide analogs capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds mimic the structure and activity of secreted Staphylococcus aureus proteins, Efb and the previously uncharacterized SAV1 155.

The invention relates to a folate coupling antibody drug which is a FOLATE-GSH-IgG conjugate and its preparation method and use in treatment on tumors and autoimmune diseases. FOLATE is folate or its analogue. FOLATE and glutathione (GSH) form FOLATE-GSH by amino bonds. An amino group at an IgG end is activated or IgG is reduced into an incomplete antibody or a heavy chain antibody. The activated IgG and FOLATE-GSH are coupled into the FOLATE-GSH-IgG conjugate. In folate receptor high-expression-type cancer patients or autoimmune disease patients, the FOLATE-GSH-IgG conjugate can bind specifically with high expressed folate receptors on the surface of a disease cell, can activate an antibody or complement system by IgG to mediate cytotoxicity, can improve biological response adjustment, and does not produce cytotoxicity in a normal cell without expressed folate receptors. The folate coupling antibody drug improves targeting of an antibody-drug and an immunopotentiator and solves the problem that the existing drugs for treating cancers and autoimmune diseases produce damage on normal cells.